LYRA

0.1166

2.91% -0.0035

Pre-market: .11 -0.0066 -5.66%

Lyra Therapeutics Inc (LYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Lyra Therapeutics Inc stock is traded at $0.1166, with a volume of 1.96M. It is down -2.91% in the last 24 hours and down -45.51% over the past month.

Previous Close:

$0.1201

Open:

$0.1171

24h Volume:

1.96M

Relative Volume:

1.77

Market Cap:

$7.91M

Revenue:

$1.47M

Net Income/Loss:

$-97.61M

P/E Ratio:

-0.0783

EPS:

-1.49

Net Cash Flow:

$-80.90M

1W Performance:

-25.21%

1M Performance:

-45.51%

6M Performance:

-52.43%

1Y Performance:

-97.92%

1-Day Range:

$0.1128

$0.1336

1-Week Range:

$0.1128

$0.16

52-Week Range:

$0.1128

$5.83

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name

Lyra Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

617-373-4600

Address

480 ARSENAL WAY, WATERTOWN, MA

Employee

Twitter

@LyraTx

Next Earnings Date

2025-03-12

Latest SEC Filings

LYRA's Discussions on Twitter

Compare LYRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYRA Lyra Therapeutics Inc	0.1166	7.91M	1.47M	-97.61M	-80.90M	-1.49
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral
May-07-24	Downgrade	Jefferies	Buy → Hold
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy
Aug-31-23	Initiated	H.C. Wainwright	Buy
May-24-22	Initiated	Cantor Fitzgerald	Overweight
May-26-20	Initiated	BTIG Research	Buy
May-26-20	Initiated	BofA/Merrill	Buy
May-26-20	Initiated	Jefferies	Buy
May-26-20	Initiated	William Blair	Outperform

View All

Lyra Therapeutics Inc Stock (LYRA) Latest News

Mar 28, 2025

Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa

Mar 28, 2025

Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia

Mar 28, 2025

Mar 19, 2025

Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Lyra Therapeutics stock plunges to 52-week low of $0.16 - Investing.com India

Mar 18, 2025

Mar 17, 2025

Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $4.50 - Defense World

Mar 17, 2025

Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World

Mar 17, 2025

Mar 16, 2025

Lyra Therapeutics (NASDAQ:LYRA) Earns “Neutral” Rating from HC Wainwright - Defense World

Mar 16, 2025

Mar 15, 2025

Lyra Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 15, 2025

Mar 13, 2025

Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times

Mar 13, 2025

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 13, 2025

FDA Green Light: Lyra's Nasal Polyp Treatment Advances as 52-Week Data Shows Promise - StockTitan

Mar 13, 2025

Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c) - TipRanks

Mar 13, 2025

Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Mar 11, 2025

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 11, 2025

Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025

Mar 06, 2025

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital

Mar 06, 2025

Mar 05, 2025

Dream Finders Homes (NASDAQ:DFH) Shares Gap Up Following Better-Than-Expected Earnings - Defense World

Feb 26, 2025

Feb 25, 2025

Comparing Lyra Therapeutics (NASDAQ:LYRA) & Anika Therapeutics (NASDAQ:ANIK) - Defense World

Feb 25, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down on Disappointing Earnings - Defense World

Feb 25, 2025

Head to Head Analysis: Kymera Therapeutics (NASDAQ:KYMR) and Creative Medical Technology (NASDAQ:CELZ) - Defense World

Feb 25, 2025

Feb 11, 2025

Watch this stock’s price performance: Lyra Therapeutics Inc (NASDAQ:LYRA) - US Post News

Feb 11, 2025

Feb 10, 2025